TrialSignal
Clinical trial intelligence report
Phase I and Pharmacokinetics Study to Determine the Safety of BIBX 1382 in Patients With a Solid Tumor on a Continuous Daily Oral Administration Schedule and After Single Oral and Intravenous Doses
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT00003980-Jul 28, 2026
NCT ID
NCT00003980
Status
SUSPENDED
Phase
Phase 1
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Executive brief
Investment-Ready Snapshot
BIBX 1382 is currently undergoing a Phase I clinical trial aimed at assessing its safety and pharmacokinetics in patients with solid tumors. The trial is sponsored by the European Organisation for Research and Treatment of Cancer (EORTC) and is designed to determine the maximum tolerated dose and document any antitumor activity. Given the competitive landscape of oncology therapeutics, particularly for solid tumors, successful outcomes in this trial could position BIBX 1382 favorably in a market characterized by high demand for novel treatments. However, the trial's current status is suspended, which may pose challenges for future development and investor confidence.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT00003980
Indication
Unspecified Adult Solid Tumor, Protocol Specific
Modality
small molecule
Target
Not specified in the provided data; further investigation required to determine the precise molecular or mechanistic target profile of BIBX 1382.
Intervention
BIBX 1382
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.